Trial Profile

Phase III study of Trimodulin in patients with severe Community Acquired Pneumonia including Covid-19 patients.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trimodulin (Primary)
Indications Community-acquired pneumonia; COVID 2019 infections
Focus Therapeutic Use
Sponsors Biotest AG

Most Recent Events

14 Sep 2026 Additionally, as per fifth inclusion criteria of CTP 700325631, the trial is including patients having at least one clinical respiratory parameter Blood Oxygen Levels less than or equal to 94 percent and/or radiologic evidence of COVID-19 pneumonia. Hence this CTP may include patients with COVID-19-pneumonia. However, trial main focus seems to be on COVID-2019-infections only. Please update as and when more info is available.
14 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com